EZETROL® Re-examination Study (MK0653-175)(COMPLETED)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01070953|
Recruitment Status : Completed
First Posted : February 18, 2010
Results First Posted : November 4, 2011
Last Update Posted : October 14, 2015
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||4467 participants|
|Official Title:||Re-examination Study for General Drug Use to Assess the Safety and Efficacy Profile of EZETROL® in Usual Practice|
|Study Start Date :||January 2005|
|Actual Primary Completion Date :||July 2010|
|Actual Study Completion Date :||July 2010|
EZETROL® 10 mg
Participants with Hypercholesterolemia treated with EZETROL®
- Participants With Any Clinical and/or Laboratory Adverse Experience While Being Treated With EZETROL® Within 14 Days After Treatment Discontinuation [ Time Frame: Up to 14 days after treatment discontinuation ]Participants who recieved EZETROL® and experienced any adverse event related or unrelated to EZETROL®, within 14 days after treatment.
- Mean Percent Change From Baseline to Treatment in Lipid Parameters [ Time Frame: Baseline to 4 weeks ]The mean percent change from baseline to treatment in lipid parameters (total cholesterol [TC], low-density lipoprotein [LDL] cholesterol, high-density lipoprotein [HDL] cholesterol, triglycerides[TG]) in participants who received EZETROL over 4 weeks and then had available laboratory results in Lipid Parameters.
- Overall Efficacy Evaluation of EZETROL® [ Time Frame: Baseline to 4 weeks ]Participants who received EZETROL over 4 weeks and then have been evaluated for overall efficacy assessment by investigator showing to be improved, unchanged or worsened.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01070953
|Study Director:||Medical Monitor||Merck Sharp & Dohme Corp.|